Study of human B7 homolog 1 expression in patients with hepatitis B virus infection

Figure 7 In vitro kinetic analysis of CD40 and human B7 homolog 1 expression on myeloid dendritic cells, with or without hepatitis B surface antigen pretreatment, stimulated by poly (I:C). A: The FSC and SSC of myeloid dendritic cells (mDCs) with r hepatitis B surface antigen (HBsAg) pretreatment were not altered significantly compared to those without rHBsAg pretreatment. This result suggests that the vitality of mDCs with or without HBsAg pretreatment is similar; B: Representative plots of CD40 and B7 homolog 1 (B7-H1) expression on mDCs with or without HBsAg pretreatment. Values in the upper right quadrant indicate the percentage of CD40 or B7-H1 positive cells; C: With HBsAg pretreatment, the percentage of CD40 (left) and B7-H1 (right) positive cells within mDCs were decreased significantly at 16 h, 20 h and 24 h time points (for CD40, ^aP < 0.05 at 16 h, 20 h and 24 h time point; for B7-H1, ^cP < 0.05 at 16 h and 24 h time point, n = 10); D: With HBsAg pretreatment, the MFI of CD40 (left) and B7-H1 (right) were decreased significantly at 16 h and 20 h time points ( for CD40 and B7-H1, ^aP < 0.05 at 16 h, 20 h and 24 h time point, n = 10); E: The inhibition rate was calculated using following equation: 1-MFI of CD40 or B7H1 with HBsAg pretreatment/MFI of CD40 or B7H1 without HBsAg pretreatment. The results showed that at 8 h, 16 h, 20 h and 24 h time point, the inhibition rate of CD40 was greater significantly than that of B7H1 (P < 0.05 at 8 h time point, P < 0.01 at 16 h time point, P < 0.05 at 20 h time point, P < 0.01 at 24 h time point). MFI: Mean fluorescence intensity; FSC: Forward scatter; SCC: Side scatter.